Sanara Medtech Inc (SMTI)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $297.06M
Last updated: Nov 17, 2026 at 11:02 AM ET
Sanara Medtech Inc (SMTI) Earnings: Report Dates and Results
Sanara Medtech (SMTI) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Sanara Medtech reported EPS of $0.12, above the $0.06 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SMTI has an expected report date of Mar 22, 2027.
SMTI Earnings Call
The latest SMTI earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 22 quarters below that had an estimate, SMTI beat 8, missed 12 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $28.43M, up 8.0% from $26.33M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.12 | $0.06 | N/A | +100.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 11, 2026 | $28.43M |
| Jun 30, 2026 | $0.05 | $0.02 | N/A | +150.00% | Beat | N/A | 1 | 0 up, 0 down | Aug 11, 2026 | $28.14M |
| Mar 31, 2026 | $0.04 | $0.33 | N/A | -87.69% | Miss | N/A | 1 | 0 up, 0 down | May 11, 2026 | $27.80M |
| Dec 31, 2025 | -$0.19 | $0.11 | $0.11 - $0.11 | -272.73% | Miss | N/A | 1 | 0 up, 0 down | Mar 24, 2026 | $27.52M |
| Sep 30, 2025 | -$3.52 | -$0.21 | -$0.24 - -$0.19 | N/A | N/A | N/A | 2 | 2 up, 0 down | Nov 12, 2025 | $26.33M |
| Jun 30, 2025 | -$0.23 | -$0.44 | -$0.55 - -$0.33 | +47.73% | Beat | N/A | 2 | 1 up, 1 down | Aug 13, 2025 | $25.80M |
| Mar 31, 2025 | -$0.41 | -$0.50 | N/A | +18.00% | Beat | N/A | N/A | 0 up, 0 down | May 14, 2025 | $23.43M |
| Dec 31, 2024 | -$0.18 | -$0.12 | N/A | -56.52% | Miss | N/A | N/A | 0 up, 0 down | Mar 25, 2025 | $26.31M |
| Sep 30, 2024 | -$0.34 | -$0.62 | -$0.62 - -$0.62 | +45.16% | Beat | N/A | 1 | 0 up, 0 down | Nov 12, 2024 | $21.67M |
| Jun 30, 2024 | -$0.41 | -$0.21 | -$0.21 - -$0.21 | -95.24% | Miss | N/A | 1 | 0 up, 0 down | Aug 12, 2024 | $20.16M |
| Mar 31, 2024 | -$0.21 | -$0.07 | -$0.07 - -$0.07 | -200.00% | Miss | N/A | 1 | 0 up, 0 down | May 13, 2024 | $18.54M |
| Dec 31, 2023 | -$0.03 | -$0.13 | -$0.13 - -$0.13 | +76.92% | Beat | N/A | 1 | 0 up, 0 down | Mar 25, 2024 | $17.69M |
| Sep 30, 2023 | -$0.13 | -$0.04 | N/A | -225.00% | Miss | N/A | 1 | 0 up, 0 down | Nov 13, 2023 | $16.02M |
| Jun 30, 2023 | -$0.22 | -$0.13 | -$0.13 - -$0.13 | -69.23% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2023 | $15.75M |
| Mar 31, 2023 | -$0.14 | -$0.33 | -$0.33 - -$0.33 | +57.58% | Beat | N/A | 1 | 0 up, 0 down | May 15, 2023 | $15.52M |
| Dec 31, 2022 | -$0.38 | -$0.26 | -$0.26 - -$0.26 | -46.15% | Miss | N/A | 1 | 0 up, 0 down | Mar 20, 2023 | $15.32M |
| Sep 30, 2022 | -$0.18 | -$0.32 | -$0.32 - -$0.32 | +43.75% | Beat | N/A | 1 | 0 up, 0 down | Nov 14, 2022 | $13.04M |
| Jun 30, 2022 | -$0.42 | -$0.28 | -$0.28 - -$0.28 | -50.00% | Miss | N/A | 1 | 0 up, 0 down | Aug 15, 2022 | $9.67M |
| Mar 31, 2022 | -$0.41 | -$0.41 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | May 16, 2022 | $7.81M |
| Dec 31, 2021 | -$0.48 | -$0.27 | -$0.27 - -$0.27 | -77.78% | Miss | N/A | 1 | 0 up, 0 down | Mar 30, 2022 | $7.03M |
| Sep 30, 2021 | -$0.27 | -$0.18 | -$0.18 - -$0.18 | -50.00% | Miss | N/A | 1 | N/A | Nov 12, 2021 | $5.82M |
| Jun 30, 2021 | -$0.16 | -$0.12 | N/A | -33.33% | Miss | N/A | N/A | N/A | Aug 16, 2021 | $6.28M |
| Mar 31, 2021 | -$0.17 | -$0.17 | N/A | 0.00% | In line | N/A | N/A | N/A | May 17, 2021 | $5.01M |
| Dec 31, 2020 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2021 | $4.79M |
| Sep 30, 2020 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2020 | $4.31M |
| Jun 30, 2020 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2020 | $2.97M |
| Mar 31, 2020 | -$0.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 12, 2020 | $3.52M |
| Dec 31, 2019 | -$0.44 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 26, 2020 | $3.35M |
| Sep 30, 2019 | -$0.35 | N/A | N/A | N/A | N/A | -480.0% | N/A | N/A | Nov 14, 2019 | $2.91M |
| Jun 30, 2019 | -$0.15 | N/A | N/A | N/A | N/A | -1600.0% | N/A | N/A | Aug 14, 2019 | $3.02M |
| Mar 31, 2019 | -$0.39 | N/A | N/A | N/A | N/A | -4000.0% | N/A | N/A | Apr 1, 2019 | $2.49M |
| Dec 31, 2018 | -$0.07 | N/A | N/A | N/A | N/A | -271.8% | N/A | N/A | Mar 31, 2019 | $47537 |
| Sep 30, 2018 | $0.09 | N/A | N/A | N/A | N/A | +121.4% | N/A | N/A | Nov 14, 2018 | $1.57M |
| Jun 30, 2018 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2018 | $2.26M |
| Mar 31, 2018 | $0.01 | N/A | N/A | N/A | N/A | -67.2% | N/A | N/A | May 15, 2018 | $1.96M |
| Dec 31, 2017 | $0.04 | N/A | N/A | N/A | N/A | +107.3% | N/A | N/A | Mar 29, 2018 | $1.70M |
| Sep 30, 2017 | $0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 16, 2017 | $1.55M |
| Jun 30, 2017 | -$0.08 | N/A | N/A | N/A | N/A | -250.2% | N/A | N/A | Aug 14, 2017 | $1.45M |
| Mar 31, 2017 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 4, 2017 | $1.61M |
| Dec 31, 2016 | $0.02 | N/A | N/A | N/A | N/A | +22.9% | N/A | N/A | Mar 31, 2017 | $1.75M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$4.35, after -$1.14 the year before. It was -$0.93 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$4.35 | N/A |
| Dec 31, 2024 | -$1.14 | N/A |
| Dec 31, 2023 | -$0.52 | N/A |
| Dec 31, 2022 | -$1.39 | N/A |
| Dec 31, 2021 | -$1.08 | N/A |
| Dec 31, 2020 | -$0.79 | N/A |
| Dec 31, 2019 | -$1.33 | -3164.5% |
| Dec 31, 2018 | $0.04 | N/A |
| Dec 31, 2017 | $0.03 | N/A |
| Dec 31, 2016 | -$0.93 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 2,800 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 2,812 | 6 | |
| 2025Q4 | Dec 31, 2025 | 4,575 | 4 | |
| 2025Q3 | Sep 30, 2025 | 4,688 | 6 | |
| 2025Q2 | Jun 30, 2025 | 4,540 | 7 | |
| 2025Q1 | Mar 31, 2025 | 3,497 | 7 | |
| 2024Q3 | Sep 30, 2024 | 3,945 | 9 | |
| 2024Q2 | Jun 30, 2024 | 4,487 | 12 |
2026Q1 Earnings Call
Opening remarks
Seth Yon Chief Executive Officer Thank you, operator, and welcome, everyone, to our first quarter 2026 earnings conference call. This was a strong quarter for us, which exceeded our expectations. Q1 2026 was the first full quarter in which we were entirely focused on the surgical market, and the results reflect our sharpened focus and enhanced financial model. We delivered 19% revenue growth compared to the first quarter of 2025, margin improvement and broke through to GAAP net profitability with net income from continuing operations of $0.4 million or $0.04 per diluted share. Our first quarter revenue growth was largely supported by increased sales of our soft tissue repair products, including CellerateRX and BIASURGE. Demand for our products is strong, and we're particularly pleased with our first quarter results given that our first quarter is historically our seasonally slowest sales period of the year. The quarter was also impacted by a three-day related shutdown in January, which caused us to lose three days of shipping during this period. Despite these challenges, we closed out the first quarter with the strongest sales month in company history in March, excluding October of 2024, which benefited from approximately $1.8 million of BIASURGE sales due to the industry disruption caused by Hurricane Helene. During the end of 2025 and continuing into 2026, we began strengthening our sales team to support enhanced net revenue growth and our heightened focus on the surgical market. At quarter end, we had grown our sales team to a total of 43 reps. In addition to strengthening our sales team, we're also very well positioned with a robust surgeon user network, a growing number of hospitals where our products are contracted or approved to be sold, a growing number of facilities where our products were sold during the quarter and a leading distributor network for our products that continues to expand. Let me dig into that a bit. As of quarter end, our products were contracted or approved to be sold in over 4,000 hospitals and ambulatory surgery centers throughout the United States. Our products were sold in over 1,400 facilities throughout the United States, up from more than 1,300 in the first quarter of last year. And we had agreements with more than 450 distributors compared to 400 at this time last year. Also, while it's not our practice to disclose specifics related to our active surgeon user base, I'm pleased to share that we saw solid growth in the number of surgeon users on a year-over-year basis in Q1. While most of you know this, I want to reiterate that Sanara is not subject to reimbursement risk, given we are 100% focused on the surgical setting.
Frequently Asked Questions About SMTI
When is Sanara Medtech's next earnings date?
Sanara Medtech's next earnings report is expected for Mar 22, 2027.
Did SMTI beat earnings estimates last quarter?
Yes. Sanara Medtech reported EPS of $0.12 for the quarter ended Sep 30, 2026, above the $0.06 estimate, a 100.00% surprise.
What EPS do analysts expect from SMTI next quarter?
The consensus EPS estimate for Sanara Medtech for the quarter ending Dec 31, 2026 is $0.14 from 5 analysts, with estimates from $0.11 to $0.19.
How often does SMTI beat earnings estimates?
Sanara Medtech beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of -7.01%.
SMTI pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors